https://www.europeanurology.com/article/S0302-2838(13)01040-3/pdf/eau-guidelines-on-prostate-cancer-part-1-screening-diagnosis-and-local-treatment-with-curative-intent-update-2013

EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent—Update 2013

The introduction of an effective blood test, prostate specific antigen (PSA), has made it possible to diagnose more and more men in an earlier stage where they can be offered potentially curative treatments. The other side of the coin is that if effective diagnostic procedures are used unselectively in elderly men with a short life expectancy, a problem with over diagnosis and over treatment might occur. Thus the same stage of prostate cancer may need different treatment strategies, pending on the patient’s life expectancy. This, and many other issues regarding the disease, is the subject of the EAU guidelines on prostate cancer. G UI DE LI N ES O N P RO ST AT E CA N CE R 10

/pdf/guidelines-on-prostate-cancer-xdnunn4th8.pdf

Guidelines on Prostate Cancer

The expression of prostate-specific membrane antigen (PSMA) is increased in prostate cancer. Recently, 68Ga-PSMA (Glu-NH-CO-NH-Lys-(Ahx)-[68Ga(HBED-CC)]) was developed as a PSMA ligand. The aim of this study was to investigate the detection rate of 68Ga-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy. Methods: Two hundred forty-eight of 393 patients were evaluable for a retrospective analysis. Median prostate-specific antigen (PSA) level was 1.99 ng/mL (range, 0.2–59.4 ng/mL). All patients underwent contrast-enhanced PET/CT after injection of 155 ± 27 MBq of 68Ga-PSMA ligand. The detection rates were correlated with PSA level and PSA kinetics. The influence of antihormonal treatment, primary Gleason score, and contribution of PET and morphologic imaging to the final diagnosis were assessed. Results: Two hundred twenty-two (89.5%) patients showed pathologic findings in 68Ga-PSMA ligand PET/CT. The detection rates were 96.8%, 93.0%, 72.7%, and 57.9% for PSA levels of ≥2, 1 to 6, 4–6, and

https://jnm.snmjournals.org/content/jnumed/56/5/668.full.pdf

Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy

PURPOSE: To compare a T1-weighted, three-dimensional (3D), gradient-echo (GRE) sequence for magnetic resonance (MR) imaging of the body (volumetric interpolated breath-hold examination, or VIBE) with a two-dimensional (2D) GRE breath-hold equivalent. MATERIALS AND METHODS: Twenty consecutive patients underwent 1.5-T MR imaging. The examinations included pre- and postcontrast (20 mL gadopentetate dimeglumine) fat-saturated 2D GRE breath-hold imaging and fat-saturated volumetric interpolated breath-hold imaging before, during (arterial phase), and after injection, with thin (2-mm source images) and thick (8-mm reconstruction images) sections. The three images were compared qualitatively and quantitatively (signal-to-noise ratio [SNR] and contrast-to-noise ratio [CNR]). RESULTS: Qualitatively, the 2-mm source images had poorer pancreatic edge definition on precontrast images compared with the other two data sets (P < .05). On gadolinium-enhanced images, scores for clarity of pancreatic edge, number of vessel...

Abdominal MR Imaging with a Volumetric Interpolated Breath-hold Examination

The Management of Peyronie's Disease: Evidence‐based 2010 Guidelines

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. a new proposal based on a two institution experience on 784 consecutive n+ patients

Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion.

Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001).

A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment

/pdf/combination-of-adjuvant-hormonal-and-radiation-therapy-1n5igtd1bp.pdf

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pn+ prostate cancer: Results of a matched analysis

L. Da Pozzo

Papers

Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. a new proposal based on a two institution experience on 784 consecutive n+ patients

Thermo-chemotherapy and electromotive drug administration of mitomycin C in superficial bladder cancer eradication. a pilot study on marker lesion.

Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001).

A new approach using local combined microwave hyperthermia and chemotherapy in superficial transitional bladder carcinoma treatment

Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pn+ prostate cancer: Results of a matched analysis